title: Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.
abstract: BACKGROUND
  Novel targeted agents have been increasingly developed and tested in clinical trials over the past 5-10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib-associated photoallergic dermatitis while enrolled on a phase 1 clinical trial.
  
  
  METHODS
  A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma presented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with vandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and supportive care provided including topical and oral steroid administration. Her cutaneous eruption improved and she was successfully re-challenged with vandetanib.
  
  
  CONCLUSIONS
  Tyrosine kinase inhibitors, such as typo-vandetinib, with various therapeutic targets have come to the forefront of oncologic therapy in recent years. It is important to have a better understanding of the side effect profile and management in order to anticipate adverse events and maintain patient safety in future clinical trials.
authors.affiliation: Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. jbgoldstein@mdanderson.org.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Goldstein
authors.affiliation: Department of Dermatology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. apatel11@mdanderson.org.
authors.forename: Anisha B
authors.initials: AB
authors.lastname: Patel
authors.affiliation: Department of Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. jlcurry@mdanderson.org.
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Curry
authors.affiliation: Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX, 77030, USA. vsubbiah@mdanderson.org.
authors.forename: Vivek
authors.initials: V
authors.lastname: Subbiah
authors.affiliation: Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX, 77030, USA. spihapau@mdanderson.org.
authors.forename: Sarina
authors.initials: S
authors.lastname: Piha-Paul
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017454:Dermatitis, Photoallergic / Q000209:etiology*; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000009:adverse effects*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011799:Quinazolines; D000068338:Everolimus; D011505:Protein-Tyrosine Kinases; C452423:vandetanib